Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine vs electroconvulsive therapy for suicidal risk in major depressive episodes
ChiCTR2300071697Phase 4Not yet recruiting
- Sponsor
- The Affiliated Brain Hospital of Guangzhou Medical University
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in major depressive disorder (MDD), bipolar disorder (BD) and suicidal ideation (2 arms), sponsored by The Affiliated Brain Hospital of Guangzhou Medical University. Primary endpoint: Beck Scale for Suicide Ideation. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)suicidal ideation
Beyond the preview
Go deeper on ChiCTR2300071697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071697.